Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.

Literature DB >> 17005836

In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.

Anne-Marie Bourgault¹, François Lamothe, Vivian G Loo, Louise Poirier.

Abstract

Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.

Entities: Chemical Species

Mesh：

Substances：
Anti-Bacterial Agents

Year: 2006 PMID： 17005836 PMCID： PMC1610058 DOI： 10.1128/AAC.00479-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

16 in total

1. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates.

Authors: J Freeman; M H Wilcox
Journal: J Antimicrob Chemother Date: 2001-02 Impact factor: 5.790

2. Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains.

Authors: Warren N Fawley; Mark H Wilcox
Journal: J Clin Microbiol Date: 2002-09 Impact factor: 5.948

3. Clostridium difficile: a formidable foe.

Authors: Vivian G Loo; Michael D Libman; Mark A Miller; Anne-Marie Bourgault; Charles H Frenette; Mirabelle Kelly; Sophie Michaud; Tuyen Nguyen; Louise Poirier; Anne Vibien; Ruth Horn; Pierre J Laflamme; Pierre René
Journal: CMAJ Date: 2004-07-06 Impact factor: 8.262

4. The new Clostridium difficile--what does it mean?

Authors: John G Bartlett; Trish M Perl
Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245

Review 5. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948

6. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors: Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal: Clin Infect Dis Date: 2005-04-25 Impact factor: 9.079

7. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors: Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal: Clin Infect Dis Date: 2005-04-25 Impact factor: 9.079

8. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study.

Authors: F Barbut; G Corthier; Y Charpak; M Cerf; H Monteil; T Fosse; A Trévoux; B De Barbeyrac; Y Boussougant; S Tigaud; F Tytgat; A Sédallian; S Duborgel; A Collignon; M E Le Guern; P Bernasconi; J C Petit
Journal: Arch Intern Med Date: 1996-07-08

9. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors: Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal: CMAJ Date: 2004-08-31 Impact factor: 8.262

10. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method.

Authors: C Coutant; D Olden; J Bell; J D Turnidge
Journal: Diagn Microbiol Infect Dis Date: 1996-05 Impact factor: 2.803

29 in total

1. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors: Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal: J Clin Microbiol Date: 2008-02-20 Impact factor: 5.948

2. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

Authors: James A Karlowsky; Nancy M Laing; George G Zhanel
Journal: Antimicrob Agents Chemother Date: 2008-08-25 Impact factor: 5.191

3. TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing.

Authors: Jordi M Lanis; Logan D Hightower; Aimee Shen; Jimmy D Ballard
Journal: Mol Microbiol Date: 2012-02-28 Impact factor: 3.501

Review 4. Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors: Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal: World J Gastrointest Pharmacol Ther Date: 2014-02-06

5. Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.

Authors: Dazhi Jin; Yun Luo; Chen Huang; Jian Cai; Julian Ye; Yi Zheng; Liqian Wang; Peng Zhao; Anbing Liu; Weijia Fang; Xianjun Wang; Shichang Xia; Jianmin Jiang; Yi-Wei Tang
Journal: J Clin Microbiol Date: 2016-12-14 Impact factor: 5.948

Review 6. Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors: Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal: Expert Rev Anti Infect Ther Date: 2014-01 Impact factor: 5.091

7. Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.

Authors: Rodica Gilca; Elise Fortin; Charles Frenette; Yves Longtin; Marie Gourdeau
Journal: Antimicrob Agents Chemother Date: 2011-11-21 Impact factor: 5.191